Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.660
-0.040 (-0.85%)
Aug 20, 2026, 4:00 PM EDT - Market closed

Cytek Biosciences Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Cytek Biosciences stock has a consensus rating of "Buy" and an average price target of $5.56. The average 1-year stock price forecast is 19.31% higher than the current stock price, while the lowest is $4.75 (+1.93%) and the highest is $7.50 (+60.94%).

Price Target: $5.56 (+19.31%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.75$5.56$5.00$7.50
Change+1.93%+19.31%+7.30%+60.94%

Analyst Ratings

The average analyst rating for Cytek Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jul '26Aug '26
Strong Buy111111
Buy111111
Hold332222
Sell000000
Strong Sell000000
Total554444

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Hold
Maintains
$5.5$5
HoldMaintains$5.5$5+7.30%Aug 6, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$7.5
BuyReiterates$7.5+60.94%Aug 6, 2026
TD Cowen
TD Cowen
Hold
Maintains
$5
HoldMaintains$5+7.30%Aug 6, 2026
Stephens
Stephens
Buy
Reiterates
$4.75
BuyReiterates$4.75+1.93%May 13, 2026

Financial Forecast

Revenue This Year
209.43M
from 201.49M
Increased by 3.94%
Revenue Next Year
223.24M
from 209.43M
Increased by 6.59%
EPS This Year
-0.12
from -0.31
EPS Next Year
0.07
from -0.12
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
127.95M164.04M193.02M200.45M201.49M209.43M
Revenue Growth
37.82%28.20%17.67%3.85%0.52%3.94%
Gross Profit
79.14M100.97M109.43M111.11M104.46M114.77M
Gross Margin
61.86%61.56%56.69%55.43%51.84%54.80%
Operating Income
9.16M-1.80M-27.85M-20.52M-40.38M-44.70M
Net Income
3.05M2.58M-12.15M-6.02M-66.54M-42.41M
EPS
-----0.31-0.12
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High210.1M
Avg209.4M
Low209.0M

Revenue Growth

Revenue Growth202620272028
High
4.3%
Avg
3.9%
Low
3.7%

EPS Forecast

EPS202620272028
High-0.12
Avg-0.12
Low-0.12

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-